As of Nov 19, 2026, 0 of 2 active firms rate GSK a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GSK EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect GlaxoSmithKline PLC ADR to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $4.76, growing to $4.96 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $33.8B, rising to $35.3B next year.
Top analysts covering GlaxoSmithKline PLC ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GSK.
#1
EF
Emily Field
Barclays
Sell
No targeton GSK
Coverage
—
+ Follow
#2
JG
James Gordon
Barclays
Sell
No targeton GSK
Coverage
—
+ Follow
#3
SJ
Sachin Jain
Bank of America Securities
Sell
$1700.00+3399.7% to target
Coverage
—
+ Follow
#4
ML
Michael Leuchten
Jefferies
Buy
No targeton GSK
Coverage
—
+ Follow
GSK stock forecast FAQ
Is GSK stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
How many active Wall Street firms cover GSK?+
2 active firms have a recognized rating on GlaxoSmithKline PLC ADR as of Nov 19, 2026.
Who is the most accurate analyst covering GSK?+
Among analysts who currently cover GSK, Emily Field of Barclays has the strongest overall Quantellect track record. Their current call is Sell.
What is GlaxoSmithKline PLC ADR's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $4.76, rising to $4.96 the following year.
How much revenue is GlaxoSmithKline PLC ADR expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $33.8B, growing to $35.3B next year.
Have analysts been upgrading or downgrading GSK lately?+
As of Nov 19, 2026, 0 of 2 active firms rate GSK a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GSK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.